Olumiant (baricitinib)

baricitinib · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Olumiant (baricitinib), covering 2025-07-17 to 2025-07-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Baricitinib in Participants With Rheumatoid Arthritis [Phase 4]